ASS1 (Argininosuccinate Synthase 1) antibodies target the enzyme responsible for catalyzing the penultimate step in arginine biosynthesis. This enzyme converts citrulline and aspartate to argininosuccinate in the urea cycle . ASS1 dysfunction is linked to metabolic disorders and cancers, making its antibodies critical for diagnostic and therapeutic research .
Format: Monoclonal or polyclonal IgG antibodies, typically with κ light chains .
Epitopes: Target specific regions of ASS1, such as amino acids 1–412 or internal domains .
Specificity: Validated via Western blot (WB), immunohistochemistry (IHC), and knockout cell controls .
Mechanism: Binds to PHGDH (phosphoglycerate dehydrogenase), promoting its ubiquitination and degradation, thereby inhibiting serine synthesis and cancer proliferation .
Key Data:
| Study Model | Outcome |
|---|---|
| TNBC Cell Lines | ASS1 overexpression reduces cell proliferation by 60% . |
| Serine Deprivation | ASS1 knockdown rescues proliferation, confirming metabolic dependency . |
Knockout Validation: ASS1 signal loss in CRISPR-edited HeLa cells confirms antibody specificity .
Cross-reactivity: Minor bands observed in wild-type cells, necessitating stringent controls .
Stability: ASS1 antibodies exhibit consistent performance under reducing conditions .
This antibody targets ASA1, a subunit of anthranilate synthase (AS). AS catalyzes the two-step biosynthesis of anthranilate, an essential intermediate in the production of L-tryptophan. In the first step, the glutamine-binding beta subunit of AS (ASB1) provides the glutamine amidotransferase activity, generating ammonia. This ammonia, along with chorismate, is used in the second step, catalyzed by the large alpha subunit of AS (ASA1), to produce anthranilate. ASA1 plays a critical regulatory role in auxin production via the tryptophan-dependent biosynthetic pathway.